Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Macular Degeneration Agents Need Randomized Trials, Medicare Panel Says

Executive Summary

Manufacturers developing treatments for age-related macular degeneration (AMD) should conduct randomized, controlled trials, the Centers for Medicare & Medicaid Services' Medicare Coverage Advisory Committee recommended at a Nov. 29 meeting in Baltimore

You may also be interested in...

MEDCAC Review Of Anti-VEGF Drugs Rescheduled To March 21, 2012

Panel will consider benefits of Avastin, Lucentis in diabetic macular edema, addressing questions released by CMS.

OSI Takes Wait-And-See Approach To Lucentis Impact On Macugen

An early 2006 launch of Genentech's wet age-related macular degeneration candidate Lucentis could impact sales of OSI/Eyetech's competing therapy, Macugen, by an estimated $75 mil. that year, OSI said

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts